🔎 Trials Near Me

Home › Scleroderma › Massachusetts

Pag-aaral pangklinika para sa Scleroderma sa Massachusetts

7 pag-aaral para sa Scleroderma ang naghahanap ng mga kalahok sa mga site sa Massachusetts.

Mga Lungsod sa Massachusetts

Opisyal na teksto ng pag-aaral (English)

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT03816345

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  • Massachusetts General Hospital, Boston
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07497087

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

  • Boston Medical Center, Boston
Nagre-recruitPhase 1
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT06925542

Platform Clinical Study for Conquering Scleroderma

  • Massachusetts General Hospital, Boston
  • Boston University (BU), Boston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06195072

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

  • Shapiro Outpatient Rheumatology Clinic at Boston Medical Center, Boston
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT07090226

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  • Brigham And Womens Hospital, Boston
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT07115745

Open Label Treprostinil Raynaud's Study

  • Brigham and Women's Hospital, Boston
  • Brigham and Women's Hospital, Boston
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT07112183

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.